NEWTOWN, Pa. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it will present an abstract relating to the mechanism of action
Independent Data Monitoring Committee (DMC) recommends continuation of INSPIRE trial with trial expansion per adaptive design based on interim analysis results for overall survival Trial Executive Committee unanimously agreed to continue the Intent To Treat (ITT) study population and increase
Agreement related to study of rigosertib in pediatric RASopathies Clinical trial in pediatric patients to be conducted by the National Cancer Institute RASopathies are orphan diseases believed to be caused by molecular defects in the RAS pathway NEWTOWN, Pa. , Jan.
NEWTOWN, Pa. , Dec. 28, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at Biotech Showcase
HanX to commercialize in Greater China : Onconova retains rights in rest of the world HanX will fund studies towards Investigational New Drug (IND) applications in both the US and China Agreement includes licensing fee, customary milestone payments and royalties on sales NEWTOWN, Pa. , Dec.
Oral rigosertib as a single agent demonstrates activity in a Phase 2 trial for lower-risk MDS 32% of 62 evaluable patients, and 44% of patients receiving optimal dosing, achieved transfusion independence New data on the molecular basis of the combination therapy with rigosertib and azacitidine in
NEWTOWN, Pa. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at the LD Micro
Novel formulation of rigosertib with enhanced bioavailability and stability Liver microsomal stability of ON 123300, a first-in-class dual inhibitor of CDK4/6 + ARK5 Formulation approaches to augment bioavailability of ON 123300 NEWTOWN, Pa. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Onconova
Rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood counts Patients with response or stable disease had one year longer survival than non-responders Rigosertib was well tolerated and a recommended dose for further evaluation was established NEWTOWN, Pa. , Nov.
NEWTOWN, Pa. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS) today announced that it
NEWTOWN, Pa. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, November 9, 2017 NEWTOWN, Pa. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that two abstracts relating to the Company's lead product candidate,
NEWTOWN, Pa. , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that they will present and
NEWTOWN, Pa. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that it will host a